ID

31680

Descrição

TIght COntrol of Psoriatic Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01106079

Link

https://clinicaltrials.gov/show/NCT01106079

Palavras-chave

Versões (1)
  1. 20/09/2018 20/09/2018 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

20 de setembro de 2018

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Psoriatic Arthritis NCT01106079

Inglês

Eligibility Psoriatic Arthritis NCT01106079

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients with a diagnosis of psoriatic arthritis by a consultant rheumatologist with less than 24 months disease duration.
Descrição

Psoriatic Arthritis Disease length

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0003872
UMLS CUI [1,2]
C0872146
active disease defined by at least one tender or swollen joint or active enthesitis.
Descrição

Disease Tender joint count | Disease Swollen joint count | Enthesitis

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0451530
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0451521
UMLS CUI [3]
C1282952
age ≥18 years at the time of signing the informed consent form and either male or female patients.
Descrição

Age

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0001779
patient understands the objectives of the study and is able and willing to sign the informed consent form.
Descrição

Comprehension Study Protocol | Informed Consent

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0162340
UMLS CUI [1,2]
C2348563
UMLS CUI [2]
C0021430
men and women of child bearing potential (wcbp) must use at least one adequate birth control measure for the duration of the study and should continue such precautions for 6 months after receiving the last dose of protocol treatment.
Descrição

Gender Contraceptive methods Quantity | Childbearing Potential Contraceptive methods Quantity

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0700589
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0700589
UMLS CUI [2,3]
C1265611
adequate full blood count within 28 days before randomisation:
Descrição

Complete Blood Count

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0009555
haemoglobin count > 8.5 g/dl
Descrição

Hemoglobin measurement

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0518015
white blood count (wbc) > 3.5 x 10*9/l
Descrição

White Blood Cell Count procedure

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0023508
absolute neutrophil count (anc) > 1.5 x 10*9/l
Descrição

Absolute neutrophil count

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0948762
platelet count > 100 x 10*9/l
Descrição

Platelet Count measurement

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0032181
adequate hepatobiliary function within 28 days before randomisation:
Descrição

Hepatobiliary System function

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1711359
UMLS CUI [1,2]
C0031843
*alt and/or ast levels must be within 3 times the upper limit of normal range (uln) for the laboratory conducting the test.
Descrição

Alanine aminotransferase increased | Aspartate aminotransferase increased

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0151905
UMLS CUI [2]
C0151904
the patient must be able to adhere to the study visit schedule and other protocol requirements.
Descrição

Protocol Compliance

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0525058
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
previous treatment for articular disease with disease modifying drugs (dmards) including, but not limited to, methotrexate, sulfasalazine, leflunomide,
Descrição

Prior Therapy Arthropathy | Antirheumatic Drugs, Disease-Modifying | Methotrexate | Sulfasalazine | leflunomide

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0022408
UMLS CUI [2]
C0242708
UMLS CUI [3]
C0025677
UMLS CUI [4]
C0036078
UMLS CUI [5]
C0063041
women who are pregnant, lactating or planning pregnancy within 6 months of their last dose of protocol treatment.
Descrição

Pregnancy | Breast Feeding | Pregnancy, Planned

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0032992
use of any investigational agents within 4 weeks or within 5 half-lives of the investigational agent, whichever is longer, prior to randomisation.
Descrição

Investigational New Drugs

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0013230
Voltar ao início da página

Similar models

Eligibility Psoriatic Arthritis NCT01106079

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Psoriatic Arthritis Disease length
Item
patients with a diagnosis of psoriatic arthritis by a consultant rheumatologist with less than 24 months disease duration.
boolean
C0003872 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Disease Tender joint count | Disease Swollen joint count | Enthesitis
Item
active disease defined by at least one tender or swollen joint or active enthesitis.
boolean
C0012634 (UMLS CUI [1,1])
C0451530 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C0451521 (UMLS CUI [2,2])
C1282952 (UMLS CUI [3])
Age
Item
age ≥18 years at the time of signing the informed consent form and either male or female patients.
boolean
C0001779 (UMLS CUI [1])
Comprehension Study Protocol | Informed Consent
Item
patient understands the objectives of the study and is able and willing to sign the informed consent form.
boolean
C0162340 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2])
Gender Contraceptive methods Quantity | Childbearing Potential Contraceptive methods Quantity
Item
men and women of child bearing potential (wcbp) must use at least one adequate birth control measure for the duration of the study and should continue such precautions for 6 months after receiving the last dose of protocol treatment.
boolean
C0079399 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C3831118 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Complete Blood Count
Item
adequate full blood count within 28 days before randomisation:
boolean
C0009555 (UMLS CUI [1])
Hemoglobin measurement
Item
haemoglobin count > 8.5 g/dl
boolean
C0518015 (UMLS CUI [1])
White Blood Cell Count procedure
Item
white blood count (wbc) > 3.5 x 10*9/l
boolean
C0023508 (UMLS CUI [1])
Absolute neutrophil count
Item
absolute neutrophil count (anc) > 1.5 x 10*9/l
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelet count > 100 x 10*9/l
boolean
C0032181 (UMLS CUI [1])
Hepatobiliary System function
Item
adequate hepatobiliary function within 28 days before randomisation:
boolean
C1711359 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
Alanine aminotransferase increased | Aspartate aminotransferase increased
Item
*alt and/or ast levels must be within 3 times the upper limit of normal range (uln) for the laboratory conducting the test.
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
Protocol Compliance
Item
the patient must be able to adhere to the study visit schedule and other protocol requirements.
boolean
C0525058 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Prior Therapy Arthropathy | Antirheumatic Drugs, Disease-Modifying | Methotrexate | Sulfasalazine | leflunomide
Item
previous treatment for articular disease with disease modifying drugs (dmards) including, but not limited to, methotrexate, sulfasalazine, leflunomide,
boolean
C1514463 (UMLS CUI [1,1])
C0022408 (UMLS CUI [1,2])
C0242708 (UMLS CUI [2])
C0025677 (UMLS CUI [3])
C0036078 (UMLS CUI [4])
C0063041 (UMLS CUI [5])
Pregnancy | Breast Feeding | Pregnancy, Planned
Item
women who are pregnant, lactating or planning pregnancy within 6 months of their last dose of protocol treatment.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
Investigational New Drugs
Item
use of any investigational agents within 4 weeks or within 5 half-lives of the investigational agent, whichever is longer, prior to randomisation.
boolean
C0013230 (UMLS CUI [1])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial